Last Price$5.86NASDAQ Previous Close - Last Trade as of 4:00PM ET 6/24/22
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change0(0.00%)
Bid (Size)$5.87 (68)
Ask (Size)$5.88 (1)
Day Low / HighN/A - N/A
Volume1.9 M

View Biotechnology IndustryPeer Comparison as of 06/24/2022


XBiotech Inc ( NASDAQ )

Price: $5.86
Change: -0.40 (6.39%)
Volume: 1.9 M
4:00PM ET 6/24/2022

Savara Inc ( NASDAQ )

Price: $1.57
Change: +0.05 (2.95%)
Volume: 350.7 K
4:00PM ET 6/24/2022

Chimerix Inc ( NASDAQ )

Price: $2.06
Change: +0.24 (13.19%)
Volume: 24.6 M
4:00PM ET 6/24/2022

Rigel Pharmaceuticals Inc ( NASDAQ )

Price: $1.02
Change: -0.10 (8.93%)
Volume: 7.9 M
4:00PM ET 6/24/2022

Personalis Inc ( NASDAQ )

Price: $4.00
Change: +0.09 (2.30%)
Volume: 5.1 M
4:00PM ET 6/24/2022

Read more news Recent News

XBiotech Says French Regulator Approves Trial of Natrunix Combination Treatment for Colorectal Cancer; Shares Rise
12:52PM ET 4/28/2022 MT Newswires

XBiotech (XBIT) said Thursday that France's National Agency for the Safety of Medicines and Health Products approved the launch of a clinical trial for its...

XBiotech Signs New Manufacturing Deal with Janssen
10:23AM ET 2/02/2022 MT Newswires

XBiotech (XBIT) said Wednesday it has signed an agreement to manufacture clinical products, including the Bermekimab antibody drug, for Johnson & Johnson's...

XBiotech Secures FDA Approval To Start Clinical Development Of Potential Rheumatology Treatment
9:56AM ET 12/13/2021 MT Newswires

XBiotech (XBIT) said Monday the US FDA has approved its investigational new drug application for Natrunix, allowing the company to start the clinical...

XBiotech Plans Clinical Study For Therapy to Reduce Brain Injury After Stroke
2:26PM ET 10/28/2021 MT Newswires

XBiotech (XBIT) said Thursday it plans to start a clinical study to test the safety and efficacy of its new True Human antibody therapy to reduce brain...

View all Commentary and Analysis

No news stories available at this time.

Company Profile

Business DescriptionXBiotech, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutic antibodies. Its product pipeline includes oncology, infectious diseases, dermatology and inflammatory disorders. The company was founded by John Simard on March 22, 2005 and is headquartered in Austin, TX. View company web site for more details
Address5217 Winnebago Lane
Austin, Texas 78744
Number of Employees53
Recent SEC Filing06/16/2022SC 13G
Chairman, President & Chief Executive OfficerJohn Simard
Vice President-Clinical OperationsAshley Otero
Secretary, VP-Finance & Human ResourcesQueena Han
Chief Scientific OfficerSushma Shivaswamy

Company Highlights

Price Open$6.28
Previous Close$6.26
52 Week Range$5.09 - 18.46
Market Capitalization$178.4 M
Shares Outstanding30.4 M
SectorHealth Technology
Next Earnings Announcement08/08/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$0.67
Beta vs. S&P 500N/A
Net Profit Margin-144.13%
Return on Equity-6.99%

Analyst Ratings as of 06/13/2019

Consensus RecommendationConsensus Icon
Powered by Factset